Highlights

  • Brokers maintain a Buy rating on COH with a price target of AUD 250.27, reflecting confidence in the second-half recovery story driven by the Nucleus Nexa implant system's commercial ramp-up, even as the stock trades at AUD 173.33.
  • First-half FY26 underlying net profit fell 9% to AUD 195 million as the Nucleus Nexa product registration and contract renewal process took longer than anticipated, with management confirming that process is now largely complete.
  • Cochlear maintained its full-year FY26 underlying net profit guidance of AUD 435–460 million, albeit at the lower end of the range, with a strong second half expected across cochlear implants, Services and Acoustics divisions.

Cochlear Limited (ASX:COH) is one of Australia's most iconic healthcare companies, a global leader in implantable hearing solutions that has spent more than four decades building a dominant franchise in cochlear implants, acoustic implants and associated sound processing technology. The company's June 2025 launch of the Cochlear Nucleus Nexa System — described as the world's first and only smart cochlear implant with upgradeable firmware — represents the culmination of a 20-year research and development investment and has become the focal point for broker and investor attention heading into calendar year 2026.

The stock currently trades at AUD 173.33, having gained AUD 1.23 or 0.71% in the most recent session, with a market capitalisation of AUD 11.25 billion. Against a broker Buy target of AUD 250.27 (As per EODHD/Others consensus rating), the implied upside of approximately 44% is substantial and speaks to a degree of market scepticism that brokers are actively challenging through their Buy thesis. Volume of 176,841 shares traded on the most recent day reflects moderate liquidity for a large-cap healthcare name, with a tight bid-offer spread of AUD 173.27 to AUD 173.38 indicative of orderly market conditions.

The Broker Buy Case: Upgradeability, Durability and Market Growth

Broker support for a Buy rating on Cochlear at AUD 250.27 is grounded in a multi-year thesis that has not fundamentally changed despite the softer first-half result. The core argument rests on three pillars: the differentiated technology position of the Nucleus Nexa, the structural growth in the global hearing loss and cognitive health market, and the company's track record of converting product launches into durable revenue and earnings growth cycles.

The Nucleus Nexa's firmware upgradeability is a genuinely novel feature in the cochlear implant space. Unlike conventional devices where software capability is locked at the point of manufacture, the Nexa platform allows for post-implantation software improvements to be delivered to patients — a feature that extends the commercial lifetime of the device, improves patient outcomes, and creates a recurring upgrade relationship that supports the Services revenue line over time. Brokers view this as a structural competitive advantage rather than a temporary differentiator.

The broader market opportunity is also compelling. Cochlear's own estimates suggest that the vast majority of people who could benefit from cochlear or acoustic implants remain untreated, reflecting a combination of awareness barriers, healthcare access constraints and clinician training capacity. The rising awareness of the link between untreated hearing loss and cognitive decline — including elevated dementia risk — is gradually shifting this dynamic, opening new avenues for demand generation in developed markets where the connection between hearing health and cognitive health is receiving increasing medical and public policy attention.

First Half FY26: A Slower Start Explained

The results for the half year ended December 2025, released on 13 February 2026, were weaker than prior expectations but not structurally concerning according to management. Sales revenue increased 1% to AUD 1,176 million in reported currency terms, though the constant currency comparison showed a 2% decline, reflecting the impact of the strong Australian dollar on translated revenues from offshore operations. Underlying net profit fell 9% to AUD 195 million, against an interim dividend held steady at AUD 2.15 per share representing a 72% payout ratio.

Management attributed the weaker result primarily to the product registration and contract renewal process for the Nucleus Nexa System, which took longer than anticipated in markets where Cochlear sought price increases to reflect the enhanced technology. This process has been described as now largely complete, clearing the path for the second half to benefit from full market availability of the Nexa system. The explanation is credible given the historical precedent of new implant launches generating a transitional drag as commercial infrastructure is reset around a new price point.

The gross margin guidance of approximately 73% for FY26 provides some context for the underlying profitability of the business even in a transitional period. R&D investment is expected to represent approximately 13% of sales revenue, reflecting the company's ongoing commitment to the next generation of product development while the Nexa platform is still in its commercial infancy. Capital expenditure guidance of AUD 100–120 million includes capacity expansion across Australian and Malaysian manufacturing sites, positioning the company for higher output volumes if demand growth accelerates as anticipated.

Second Half FY26 Outlook: The Recovery Thesis in Detail

Management's second-half expectations are notably more constructive than the first-half outcome would imply. In cochlear implants, strong revenue growth is anticipated in developed markets, driven by market growth, the broad availability of the Nucleus Nexa implant, and the finalisation of the remaining small proportion of account contract renewals during the third quarter. Emerging markets are also expected to deliver solid second-half growth through a pipeline of tenders and orders, though the timing of such approvals can be inherently unpredictable.

The Services segment — which encompasses sound processor upgrades, accessories and warranty services for the existing installed base of implant recipients — is expected to deliver strong growth in the second half. Key drivers include the increase in the eligible base as more recipients reach processor upgrade milestones, the US retirement of the older Nucleus 7 Sound Processor (which drives recipient transitions to newer processors), and the contribution from the recently launched Kanso 3 Sound Processor, a behind-the-ear device that expands the range of off-the-ear processor options available to Cochlear's existing recipient base.

Acoustics revenue — generated through the Osia and Baha product lines for patients with conductive hearing loss, single-sided deafness, and mixed hearing loss — is also expected to improve in the second half following a softer first half. The continuing geographic expansion of the Osia System and the rollout of the Baha 7 Sound Processor, launched in June 2025, are cited as the primary growth drivers in this segment.

Foreign Exchange: A Persistent Headwind

Cochlear's global revenue base makes the company inherently sensitive to currency fluctuations, and the FY26 guidance framework reflects this explicitly. The guidance of AUD 435–460 million in underlying net profit is based on exchange rate assumptions of 66 cents AUD/USD and 56 cents AUD/EUR, the same rates used in August 2025 guidance.

Management has noted that if the Australian dollar remains at its then-current elevated levels for the balance of FY26, underlying net profit would be expected to reduce by approximately AUD 30 million. The company estimates sensitivity of approximately AUD 3 million per one-cent change in the US dollar and approximately AUD 4 million per one-cent change in the Euro for the full six months of the second half. Given that the Australian dollar has strengthened materially since August 2025, this foreign exchange headwind is a genuine risk to achieving the upper end — or even the midpoint — of the guidance range.

Long-Term Strategic Position: Cognitive Health and Market Expansion

One of the most underappreciated aspects of the Cochlear investment thesis is the company's positioning at the intersection of hearing health and cognitive health. A growing body of medical research has documented the correlation between untreated hearing loss and accelerated cognitive decline, including elevated risk of dementia. As this evidence base strengthens and reaches mainstream clinical practice, the addressable market for cochlear and acoustic implants expands beyond those seeking hearing restoration and into the broader field of preventive cognitive healthcare.

Cochlear aims to help over 60,000 people hear with a cochlear or acoustic implant in FY26, a target that reflects both commercial ambitions and the company's humanitarian purpose. For FY26, management remains confident in the opportunity to grow markets sustainably, supported by strong balance sheet health, a differentiated product portfolio anchored by the Nexa platform, and rising clinical and patient awareness of the link between hearing intervention and cognitive outcomes.

Conclusion

Cochlear Limited presents a compelling case for patience at the current share price. The broker Buy rating at AUD 250.27 reflects a high-conviction view that the Nucleus Nexa System will drive a meaningful earnings recovery in the second half of FY26 and beyond, that the structural market growth opportunity in hearing health remains substantially underpenetrated, and that the company's R&D and manufacturing capabilities create a durable competitive moat. The first-half stumble — rooted in an extended Nexa contracting process rather than any competitive loss or demand weakness — appears to be resolving, and the second-half guidance framework implies a strong acceleration that brokers are comfortable underwriting. The foreign exchange environment warrants monitoring, but the underlying business quality is not in doubt.